{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:54:19Z","timestamp":1792450459003,"version":"4.5.0"},"reference-count":55,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Mastocytosis is a rare disease due to the abnormal accumulation of mast cells in various tissues. Its clinical presentation is heterogeneous depending on mast cell infiltration and mediators release. In some cases, it is associated with hematological malignancies. Prognosis varies from very good with a life expectancy similar to the general population in indolent forms of the disease to a survival time of just a few months in mast cell leukemia. Although in most cases a somatic <ns4:italic>KIT <\/ns4:italic>D816V mutation is found in tumor mast cells, the physiopathology of the disease is not yet fully understood. Additional germline and somatic mutations may explain this heterogeneity. Treatments aim at blocking effect of mast cell mediators, reducing mast cell activation and tumor burden. New drugs mainly directed against the tyrosine kinase activity of KIT have dramatically changed the quality of life and prognosis of mast cell diseases. Present and future therapeutic strategies are discussed in this review.<\/ns4:p>","DOI":"10.12688\/f1000research.19463.1","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T12:25:10Z","timestamp":1574425510000},"page":"1961","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Recent advances in the understanding and therapeutic management of mastocytosis"],"prefix":"10.12688","volume":"8","author":[{"given":"Julien","family":"Rossignol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Polivka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Maouche-Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2574-3874","authenticated-orcid":false,"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fmed.2017.00110","article-title":"Targeted Treatment Options in Mastocytosis.","volume":"4","author":"M Vaes","year":"2017","journal-title":"Front Med (Lausanne)."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"3085-94","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).","volume":"121","author":"A Pardanani","year":"2013","journal-title":"Blood."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"1420-7","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.","volume":"129","author":"P Valent","year":"2017","journal-title":"Blood."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"11-23","DOI":"10.1111\/bjh.14967","article-title":"How we diagnose and treat systemic mastocytosis in adults.","volume":"180","author":"R Scherber","year":"2018","journal-title":"Br J Haematol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1760-71","DOI":"10.3324\/haematol.2018.195867","article-title":"Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.","volume":"103","author":"M Arock","year":"2018","journal-title":"Haematologica."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"2460-6","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis.","volume":"122","author":"J Schwaab","year":"2013","journal-title":"Blood."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"661-5","DOI":"10.1182\/blood-2002-01-0203","article-title":"Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene.","volume":"100","author":"A Yavuz","year":"2002","journal-title":"Blood."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"1146-59","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.","volume":"91","author":"A Pardanani","year":"2016","journal-title":"Am J Hematol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1125-1133.e1","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.","volume":"7","author":"P Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"275-80","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms.","volume":"157","author":"I Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"180-188.e3","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.","volume":"141","author":"M Carter","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"474-90","DOI":"10.1111\/ejh.12544","article-title":"Current treatment options in patients with mastocytosis: Status in 2015 and future perspectives.","volume":"94","author":"M Arock","year":"2015","journal-title":"Eur J Haematol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"35-45","DOI":"10.1016\/j.jaci.2015.08.034","article-title":"Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology.","volume":"137","author":"K Hartmann","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1581-1590.e3","DOI":"10.1016\/j.jaci.2015.05.034","article-title":"Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis.","volume":"136","author":"T Wiechers","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"612-20","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: A randomised, placebo-controlled, phase 3 study.","volume":"389","author":"O Lortholary","year":"2017","journal-title":"Lancet."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"603-25","DOI":"10.1016\/s0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: A consensus proposal.","volume":"25","author":"P Valent","year":"2001","journal-title":"Leuk Res."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"1160-1171.e5","DOI":"10.1016\/j.immuni.2018.04.025","article-title":"Hemogenic Endothelial Fate Mapping Reveals Dual Developmental Origin of Mast Cells.","volume":"48","author":"R Gentek","year":"2018","journal-title":"Immunity."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"1609-14","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.","volume":"96","author":"B Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"804-15","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.","volume":"130","author":"C Bodemer","year":"2010","journal-title":"J Invest Dermatol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1635-41","DOI":"10.1084\/jem.20050807","article-title":"Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation.","volume":"202","author":"J Zappulla","year":"2005","journal-title":"J Exp Med."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1042-6","DOI":"10.1053\/j.gastro.2005.06.060","article-title":"Novel Germline Mutation of KIT Associated With Familial Gastrointestinal Stromal Tumors and Mastocytosis.","volume":"129","author":"K Hartmann","year":"2005","journal-title":"Gastroenterology."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"373-8","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.","volume":"30","author":"L Zhang","year":"2006","journal-title":"Leuk Res."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"e245-e247","DOI":"10.1200\/JCO.2012.42.0133","article-title":"Rare, Germline Mutation of KIT With Imatinib-Resistant Multiple GI Stromal Tumors and Mastocytosis.","volume":"31","author":"R Speight","year":"2013","journal-title":"J Clin Oncol."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"178-187.e1","DOI":"10.1016\/j.jaci.2013.12.1090","article-title":"Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.","volume":"134","author":"E Chan","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1136\/jmg.2003.015156","article-title":"A germline mutation in KIT in familial diffuse cutaneous mastocytosis.","volume":"41","author":"X Tang","year":"2004","journal-title":"J Med Genet."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1160-9","DOI":"10.1111\/j.1365-2133.2008.08827.x","article-title":"Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.","volume":"159","author":"R Foster","year":"2008","journal-title":"Br J Dermatol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"657-62","DOI":"10.1002\/1097-0142(20010801)92:3<657::aid-cncr1367>3.0.co;2-d","article-title":"Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa.","volume":"92","author":"A Beghini","year":"2001","journal-title":"Cancer."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"2735-43","DOI":"10.1200\/JCO.2005.06.009","article-title":"Familial gastrointestinal stromal tumor syndrome: Phenotypic and molecular features in a kindred.","volume":"23","author":"F Li","year":"2005","journal-title":"J Clin Oncol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"267-70","DOI":"10.1111\/pde.12381","article-title":"Novel R634W c-kit Mutation Identified in Familial Mastocytosis.","volume":"32","author":"W Pollard","year":"2015","journal-title":"Pediatr Dermatol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"859-65.e2","DOI":"10.1016\/j.exphem.2011.05.009","article-title":"Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.","volume":"39","author":"B Wasag","year":"2011","journal-title":"Exp Hematol."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"1245-51","DOI":"10.1016\/j.leukres.2014.07.010","article-title":"Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.","volume":"38","author":"P de Melo Campos","year":"2014","journal-title":"Leuk Res."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"5466-76","DOI":"10.4049\/jimmunol.180.8.5466","article-title":"Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.","volume":"180","author":"M Mayerhofer","year":"2008","journal-title":"J Immunol."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1115-22","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.","volume":"29","author":"M Jawhar","year":"2015","journal-title":"Leukemia."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"136-43","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis.","volume":"30","author":"M Jawhar","year":"2016","journal-title":"Leukemia."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1850-6","DOI":"10.1038\/s41375-018-0121-1","article-title":"A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.","volume":"32","author":"M Patnaik","year":"2018","journal-title":"Leukemia."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"5727-36","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.","volume":"113","author":"K Lim","year":"2009","journal-title":"Blood."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"744-64","DOI":"10.1111\/all.13262","article-title":"EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy.","volume":"73","author":"G Sturm","year":"2018","journal-title":"Allergy."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"753-9","DOI":"10.1097\/ALN.0000000000000031","article-title":"Perioperative management of patients with mastocytosis.","volume":"120","author":"P Dewachter","year":"2014","journal-title":"Anesthesiology."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"357-67","DOI":"10.1111\/bcp.12094","article-title":"Ketamine for chronic pain: risks and benefits.","volume":"77","author":"M Niesters","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1009-16; quiz 1050","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis.","volume":"126","author":"S Barete","year":"2015","journal-title":"Blood."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"790-4","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.","volume":"84","author":"K Lim","year":"2009","journal-title":"Am J Hematol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"230-8","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.","volume":"73","author":"S Broesby-Olsen","year":"2018","journal-title":"Allergy."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"2387-2395.e3","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.","volume":"7","author":"R Lemal","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"1481-4","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.","volume":"33","author":"A Vega-Ruiz","year":"2009","journal-title":"Leuk Res."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"3906-15","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.","volume":"14","author":"S Verstovsek","year":"2008","journal-title":"Clin Cancer Res."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"1065-72","DOI":"10.1182\/blood-2005-06-2433","article-title":"Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.","volume":"108","author":"M Gabillot-Carr\u00e9","year":"2006","journal-title":"Blood."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"4270-6","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis.","volume":"102","author":"H Kluin-Nelemans","year":"2003","journal-title":"Blood."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"483-8","DOI":"10.1007\/s12185-008-0166-4","article-title":"Advanced mast cell disease: an Italian Hematological Multicenter experience.","volume":"88","author":"L Pagano","year":"2008","journal-title":"Int J Hematol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"2530-41","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.","volume":"374","author":"J Gotlib","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"3264-74","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.","volume":"32","author":"C Ustun","year":"2014","journal-title":"J Clin Oncol."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"189-99","DOI":"10.1182\/bloodadvances.2017011551","article-title":"Variability of PD-L1 expression in mastocytosis.","volume":"2","author":"E Hatch","year":"2018","journal-title":"Blood Adv."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"1753-6","DOI":"10.1038\/leu.2016.30","article-title":"Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.","volume":"30","author":"I Alvarez-Twose","year":"2016","journal-title":"Leukemia."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"2832-41","DOI":"10.1182\/blood-2015-03-637728","article-title":"Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.","volume":"126","author":"K Blatt","year":"2015","journal-title":"Blood."},{"key":"ref-54","first-page":"2909-2909","article-title":"Phase 2 Study of Brentuximab Vedotin in Patients with Advanced Systemic Mastocytosis.","volume":"130","author":"J Baird","year":"2017","journal-title":"Blood."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"799-809","DOI":"10.3324\/haematol.2017.179895","article-title":"The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.","volume":"103","author":"M Schneeweiss","year":"2018","journal-title":"Haematologica."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-1961\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1961\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-1961\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T12:35:07Z","timestamp":1574426107000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-1961\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":55,"URL":"https:\/\/doi.org\/10.12688\/f1000research.19463.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.21341.r56549","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.21341.r56547","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.21341.r56550","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.21341.r56548","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-1961\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.21341.r56547, Uma Borate, Luke Fletcher, Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, OR, USA, 22 Nov 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1961\/v1#referee-response-56547","order":0,"name":"referee-response-56547","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.21341.r56549, Stefan W\u00f6hrl, Floridsdorf Allergy Center (FAZ), Pius-Parsch-Platz 1\/3,  Vienna, 1210, Austria, 22 Nov 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1961\/v1#referee-response-56549","order":1,"name":"referee-response-56549","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.21341.r56550, Yoseph A Mekori, Sackler Faculty of Medicine, Tel Aviv University, Kfar Saba, 4441407, Israel, 22 Nov 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1961\/v1#referee-response-56550","order":2,"name":"referee-response-56550","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.21341.r56548, Paul LA van Daele, Department of Internal Medicine, Section of Allergy, Erasmus University Medical Center, Rotterdam, The Netherlands, 22 Nov 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-1961\/v1#referee-response-56548","order":3,"name":"referee-response-56548","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":4,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}